Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006020 · ClinicalTrials.gov registry record · Phase 2
S0010 506U78 in Treating Patients With Recurrent or Refractory Acute Lymphocytic Leukemia
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT00006020 is a Phase 2 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 35 participants.
The verdict
NCT00006020, a Phase 2 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 506U78 in treating patients who have recurrent or refractory acute lymphocytic leukemia.
Interventions
- DRUG nelarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2000-07 |
| Est. Completion | 2004-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006020
The ClinicalTrials.gov registry entry for NCT00006020 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which nelarabine is the first listed.
NCT00006020 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006020 about?
NCT00006020 is a clinical study titled "S0010 506U78 in Treating Patients With Recurrent or Refractory Acute Lymphocytic Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 506U78 in treating patients who have recurrent or refractory acute lymphocytic leukemia.
What is the current status of trial NCT00006020?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2000-07. Estimated completion is 2004-07.
What interventions are being tested in trial NCT00006020?
The interventions under investigation include: nelarabine (DRUG).
Who is sponsoring clinical trial NCT00006020?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.